Docstoc

Roche---Half-Year-Report-2001

Document Sample
Roche---Half-Year-Report-2001 Powered By Docstoc
					Roche Half-Year Report 2001
Excel Download Area
All statements are unaudited
Contents Worksheet 1 Worksheet 2 Worksheet 3 Worksheet 4 Worksheet 5 Cover Sheet Consolidated Income Statement, adjusted basis Information by Division, adjusted basis Consolidated Financial Statements Business Segment (Divisional) Information Location in HYR'01 page 11 page 12 pages 13-15 pages 19

Note: For annotations to these tables, please refer to the footnotes in the half-year report.

Consolidated income statement on an adjusted basis
in millions of CHF

Six months ended 30 June Sales Cost of sales Gross profit Marketing and distribution Research and development Administration Amortisation of intangible assets Impairment of long-term assets Other operating income (expense), net Operating profit Financial income (expense), net Profit before taxes Income taxes Profit after taxes Income applicable to minority interests Share of result of associated companies Net income Diluted net earnings per share and non-voting equity security (in CHF)

2001 14,469 (4,274) 10,195 (4,132) (1,955) (606) (779) (329) 2,394 1,472 3,866 (890) 2,976 (24) 36 2,988 3.52

2000 13,679 (4,119) 9,560 (4,044) (1,900) (576) (725) 62 2,377 1,229 3,606 (660) 2,946 29 3 2,978 3.52

% Change +6 +4 +7 +2 +3 +5 +7 +1 +20 +7 +35 +1 0

Roche Half-Year Report 2001

Excel Worksheet 2

Location: HYR'01 page 11

Information by division on an adjusted basis
in millions of CHF Vitamins and Fine Chemicals

Pharmaceuticals Diagnostics Six months ended 30 June 2001 Divisional sales to third parties EBITDA - as % of sales Operating profit - as % of sales Six months ended 30 June 2000 Divisional sales to third parties EBITDA - as % of sales Operating profit - as % of sales

Other

Total

9,276 2,715 29 1,783 19

3,374 930 28 498 15

1,819 332 18 228 13

(113) (115) -

14,469 3,864 27 2,394 17

8,856 2,614 30 1,750 20

2,969 831 28 438 15

1,854 419 23 305 16

(115) (116) -

13,679 3,749 27 2,377 17

Roche Half-Year Report 2001

Excel Worksheet 3

Location: HYR'001 page 12

Interim Condensed Consolidated Financial Statements
Consolidated income statement for the six months ended 30 June
in millions of CHF 2001 Sales Cost of sales Gross profit Marketing and distribution Research and development Administration Amortisation of intangible assets Impairment of long-term assets Pharmaceuticals Division restructuring - impairment of long-term assets - other restructuring costs Other operating income (expense), net Gain from sales of Genentech sales Operating profit Financial income (expense), net Profit before taxes Income taxes Profit after taxes Change in accounting policies Income applicable to minority interests Share of result of associated companies Net income Basic earnings per share and non-voting equity security (in CHF) Diluted earnings per share and non-voting equity security (in CHF) 14,469 (4,274) 10,195 (4,132) (1,955) (606) (779) (204) (465) (329) 1,725 1,472 3,197 (692) 2,505 (24) 36 2,517 2.99 2.96 2000 14,808 (4,803) 10,005 (4,284) (1,931) (617) (760) (1,161) 41 3,949 5,242 1,183 6,425 (1,682) 4,743 1,413 44 3 6,203 7.41 7.19

Roche Half-Year Report 2001

Excel Worksheet 4

Location: HYR'01 pages 13-15

Consolidated balance sheet
in millions of CHF 30 June 31 December 2001 2000 Long-term assets Property, plant and equipment Intangible assets Other long-term assets Total long-term assets Current assets Cash and marketable securities Other current assets Total current assets Total assets Equity Minority interests Non-current liabilities Long-term debt Other non-current liabilities Total non-current liabilities Current liabilities Short-term debt Other current liabilities Total current liabilities Total equity, minority interests and liabilities

14,189 16,181 6,461 36,831

13,785 15,870 5,143 34,798

23,259 14,899 38,158 74,989 30,571 5,183

20,648 14,089 34,737 69,535 27,608 4,428

15,354 8,878 24,232

16,167 7,475 23,642

6,105 8,898 15,003 74,989

5,451 8,406 13,857 69,535

Roche Half-Year Report 2001

Excel Worksheet 4

Location: HYR'01 pages 13-15

Consolidated statement of changes in equity for the six months ended 30 June
in millions of CHF 2001 Share capital Balance at 1 January and at 30 June Non-voting equity securities (Genussscheine) Balance at 1 January and at 30 June Own equity instruments Balance at 1 January Movements during the period Balance at 30 June Retained earnings Balance at 1 January Changes in accounting policies Balance at 1 January as restated Net income Dividends paid Givaudan spin-off - special dividend and transfer of net assets Balance at 30 June Fair value and other reserves Balance at 1 January Changes in accounting policies Balance at 1 January as restated Changes in fair value during the period Equity component of new convertible debt Currency translation gains (losses) Balance at 30 June Total equity at 30 June 2000

160

160

p.m.

p.m.

(4,166) 966 (3,200)

(3,291) 2 (3,289)

31,839 (28) 31,811 2,517 (981) 33,347

26,669 26,669 6,203 (835) (2,642) 29,395

(225) 602 377 (498) 385 264 30,571

125 125 24 111 260 26,526

Roche Half-Year Report 2001

Excel Worksheet 4

Location: HYR'01 pages 13-15

Consolidated cash flow statement for the six months ended 30 June
in millions of CHF 2001 Operating activities before income taxes Income taxes paid (all activities) Operating activities Financing activities Investing activities Net effect of currency translation on cash Increase (decrease) in cash Cash at beginning of the period Cash at end of the period 2,831 (366) 2,465 (2,269) (686) 55 (435) 2,562 2,127 2000 2,643 (989) 1,654 (835) 668 10 1,497 2,052 3,549

Roche Half-Year Report 2001

Excel Worksheet 4

Location: HYR'01 pages 13-15

Information by business segment (division)
in millions of CHF Pharmaceuticals Six months ended 30 June 2001 Segment revenue / divisional sales Less inter-divisional sales Divisional sales to third parties Segment result / operating profit - as % of sales Six months ended 30 June 2000 Segment revenue / divisional sales Less inter-divisional sales Divisional sales to third parties Segment result / operating profit - as % of sales 9,365 (89) 9,276 1,114 12 Vitamins and Fine Diagnostics Chemicals 3,375 (1) 3,374 498 15 1,858 (39) 1,819 228 13 Continuing Operations 14,598 (129) 14,469 1,725 12 Fragrances and Flavours -

Other (115) -

Total 14,598 (129) 14,469 1,725 12

8,941 (85) 8,856 4,415 50

2,970 (1) 2,969 438 15

1,900 (80) 1,820 305 17

(116) -

13,811 (166) 13,645 5,042 37

1,193 (30) 1,163 200 17

15,004 (196) 14,808 5,242 35

Roche Half-Year Report 2001

Excel Worksheet 5

Location: HYR'01 pages 19


				
DOCUMENT INFO
Shared By:
Tags: Roche, ---Ha
Stats:
views:6
posted:11/28/2009
language:English
pages:8
Description: Roche---Half-Year-Report-2001